Palmitoyl Tetrapeptide-7 vs AOD-9604
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
Palmitoyl Tetrapeptide-7Fat Loss & Metabolic
AOD-9604- Summary
- Palmitoyl Tetrapeptide-7 (Rigin) is a cosmetic peptide consisting of palmitic acid linked to the tetrapeptide sequence GQPR (Gly-Gln-Pro-Arg). It was designed to mimic the biological activity of the IgG immunoglobulin C-terminus, which downregulates the production of interleukin-6 (IL-6), a key driver of skin aging and inflammation.
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- Half-Life
- Topical penetration-dependent; effects last hours to days
- 30-45 minutes injectable; longer with nasal spray formulation
- Admin Route
- Topical
- SubQ, Intranasal, Oral
- Research
- —
- —
- Typical Dose
- 2-5 ppm concentration in formulation
- 300-600 mcg
- Frequency
- Twice daily
- Once daily
- Key Benefits
- Reduces IL-6 inflammatory cytokine in skin
- Prevents 'inflammaging' of the skin
- Inhibits MMP collagen-degrading enzymes
- Synergistic with Matrixyl for anti-aging
- Clinically tested for wrinkle and skin texture improvement
- Well-tolerated topically
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Side Effects
- Contact sensitization (rare)
- Well-tolerated at standard concentrations
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Stacks With
- —
- —